Luka works across industry and the wider global health community on solutions to tackle antimicrobial resistance (AMR). He manages IFPMA’s policy and advocacy work on AMR, including related cross-functional area of vaccines for AMR.
In particular, his work focuses on enabling AMR-related innovation, and on policies to improve the impact of vaccination to mitigate the threat of AMR. Luka also supports IFPMA activities on digital health.
Previously, Luka worked in the AMR Industry Alliance Secretariat, including as an interim Secretariat Lead. He was heavily involved in the International Pharmaceutical Students’ Federation (IPSF), where he spent a year in its executive committee as the Chairperson of the European Regional Office.
Luka holds a master’s degree in Pharmacy from the University of Ljubljana, Slovenia. He completed part of his master thesis at the Utrecht Institute for Pharmaceutical Sciences in the Netherlands.
More from Luka
Rebuilding momentum on antibiotics research, giving innovators a chance to pull through
The pace of resistance to existing antibiotics is outpacing the rate at which new ones can reach the market and be used against difficult-to-treat infections.
Youth perspective: The AMR burden and opportunities to overcome it
Sometimes dubbed the “silent pandemic,” Antimicrobial Resistance (AMR) is a natural phenomenon that occurs when microorganisms such as bacteria adapt after repeated exposure to antibiotics, rendering treatments ineffective. It has been at the top of the global health agenda for many years, and young professionals in healthcare are acutely aware of it.